Terms ending in 2027
Every in-force patent on Intervet Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,197,827 | Protein from Photobacterium Damselae and Use Thereof In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 7,879,809 | Fish Production In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 8,034,845 | Compositions and Method for Treating Infection in Cattle and Swine In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 8,084,445 | Pharmaceutical Formulation In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 8,137,678 | Canine Lyme Disease Vaccine In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 7,718,772 | Canine Thymic Stromal Lymphopoietin Protein and Uses Thereof In force · High confidence | Intervet Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.